ISIS PHARMACEUTICALS INC's ticker is ISIS and the CUSIP is 464330109. A total of 347 filers reported holding ISIS PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is 1.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2015 | $54,234,000 | -29.6% | 1,341,757 | +0.3% | 0.02% | -29.2% |
| Q2 2015 | $76,989,000 | -8.2% | 1,337,782 | +1.5% | 0.02% | -11.1% |
| Q1 2015 | $83,890,000 | +27.7% | 1,317,597 | +23.8% | 0.03% | +28.6% |
| Q4 2014 | $65,698,000 | +11.6% | 1,064,099 | -29.8% | 0.02% | +5.0% |
| Q3 2014 | $58,878,000 | -2.2% | 1,516,305 | -13.3% | 0.02% | +5.3% |
| Q2 2014 | $60,225,000 | -7.7% | 1,748,178 | +15.7% | 0.02% | -9.5% |
| Q1 2014 | $65,281,000 | +136.0% | 1,510,795 | +117.6% | 0.02% | +110.0% |
| Q4 2013 | $27,657,000 | +4.0% | 694,189 | -2.0% | 0.01% | 0.0% |
| Q3 2013 | $26,601,000 | +93.1% | 708,602 | +38.2% | 0.01% | +66.7% |
| Q2 2013 | $13,776,000 | +101.6% | 512,700 | -21.7% | 0.01% | +100.0% |
| Q4 2012 | $6,832,000 | +24.7% | 654,405 | +68.1% | 0.00% | +50.0% |
| Q3 2012 | $5,478,000 | +98.8% | 389,362 | +69.6% | 0.00% | +100.0% |
| Q2 2012 | $2,756,000 | +392.1% | 229,636 | +260.0% | 0.00% | – |
| Q1 2012 | $560,000 | – | 63,793 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BB BIOTECH AG | 7,202,585 | $270,385,000 | 14.71% |
| DOWLING & YAHNKE LLC | 675,798 | $25,369,000 | 3.98% |
| GARRISON BRADFORD & ASSOCIATES INC | 100,700 | $3,780,000 | 3.87% |
| WILLIAM HARRIS INVESTORS INC | 312,834 | $11,743,000 | 3.67% |
| Meditor Group Ltd | 490,000 | $18,395,000 | 2.59% |
| AVALON CAPITAL MANAGEMENT | 50,943 | $1,912,000 | 1.89% |
| Orinda Asset Management LLC | 14,665 | $551,000 | 1.73% |
| PINNACLE ASSOCIATES LTD | 2,064,760 | $77,511,000 | 1.60% |
| PERKINS CAPITAL MANAGEMENT INC | 52,850 | $1,984,000 | 1.43% |
| NCM Capital Advisers, Inc. | 24,950 | $937,000 | 1.04% |